Lupin to Acquire VISUfarma from GHO Capital

Faes Farma to Acquire SIFI to Build Leading Ophthalmology Franchise

June 10, 2025

Healthcare Services

SIFI shareholders have signed an agreement to sell 100% of SIFI shares to Faes Farma, a European pharmaceutical company listed on the Spanish stock exchange. The deal is expected to close in Q3 2025, subject to regulatory approvals and Faes Farma’s extraordinary shareholders’ meeting.

Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

August 19, 2024

Healthcare Services

Visiox Pharmaceuticals, Inc. entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., an ophthalmic pharmaceutical company focused on developing and commercializing therapies for glaucoma and other eye disorders. The combined company will operate under the Ocuvex name, aiming to strengthen its ophthalmic portfolio and accelerate commercialization of near-term products.

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.

Nordic Pharma (via Amring) Acquires Visant Medical to Launch LACRIFILL in U.S.

December 18, 2023

Medical Devices

Nordic Pharma Group B.V., through its U.S. subsidiary Amring Pharmaceuticals Inc., has completed the acquisition of Visant Medical, Inc., bringing the FDA-cleared hyaluronic acid canalicular occlusive device LACRIFILL into the Nordic Pharma portfolio. Nordic will launch and commercialize LACRIFILL in the United States, expanding its ophthalmology product offering and enabling future global regulatory filings.

Unifeye Vision Partners Acquires Insight Vision Group

September 18, 2023

Healthcare Services

Unifeye Vision Partners, a portfolio company of Waud Capital, has acquired Insight Vision Group, a California-based ophthalmology platform that combines DLV Vision and ADV Vision. The deal adds 10 clinics and 2 ambulatory surgery centers to Unifeye's network and expands the buyer's West Coast footprint; financial terms were not disclosed.